High-dose IL-2 for metastatic renal cell carcinoma: can the first antitumor immunotherapy be reinvented?

Immunotherapy. 2014;6(9):955-8. doi: 10.2217/imt.14.78.
No abstract available

Keywords: immunotherapy; interleukin-2; kidney cancer; metastatic renal cell carcinoma.

Publication types

  • Editorial

MeSH terms

  • CD4-Positive T-Lymphocytes / immunology
  • Carcinoma, Renal Cell / drug therapy
  • Carcinoma, Renal Cell / immunology
  • Carcinoma, Renal Cell / secondary*
  • Cytokines / blood
  • Humans
  • Immunotherapy / adverse effects
  • Interleukin-2 / administration & dosage*
  • Interleukin-2 / blood
  • Interleukin-2 / immunology
  • Kidney Neoplasms / drug therapy*
  • Kidney Neoplasms / immunology
  • T-Lymphocyte Subsets / immunology
  • T-Lymphocytes, Cytotoxic / immunology
  • T-Lymphocytes, Regulatory / immunology

Substances

  • Cytokines
  • Interleukin-2